Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a biopharmaceutical company focused on developing treatments for neurological and endocrine-related disorders. The company is known for its innovative therapies and has a strong presence in the pharmaceutical industry. Neurocrine competes with other biotech firms in the market, striving to bring effective solutions to patients with unmet medical needs.
On November 28, 2025, Canaccord Genuity reiterated its "Buy" rating for NBIX, with the stock priced at $151.58. This rating suggests confidence in the company's future performance. Despite the "Buy" rating, the action associated with it is "hold," indicating that investors might consider maintaining their current positions rather than buying more shares immediately.
Capital Fund Management S.A. has shown increased confidence in NBIX by boosting its holdings by 15.9% in the recent quarter. The fund now owns 203,628 shares, valued at approximately $25.6 million. This investment represents 0.21% of Neurocrine's total shares, highlighting the fund's belief in the company's potential growth.
Other institutional investors have also adjusted their positions in NBIX. Geneos Wealth Management Inc. significantly increased its holdings by 143.6%, now owning 229 shares valued at $25,000. WPG Advisers LLC acquired a new stake valued at around $32,000 during the first quarter, indicating growing interest from various investors.
The stock for NBIX is currently priced at $151.58, reflecting a 5.61% increase or $8.05. Today, the stock fluctuated between $146 and $153.54. Over the past year, NBIX has seen a high of $157.67 and a low of $84.23. With a market capitalization of approximately $15.07 billion, NBIX remains a significant player in the biopharmaceutical industry.
